布地奈德雾化吸入治疗小儿哮喘急性发作的疗效及血清炎性因子水平的变化

目的:探讨布地奈德雾化吸入治疗小儿哮喘急性发作的疗效及血清炎性因子水平的变化。方法:选择2016年1月至2017年12月于我院治疗的90例小儿哮喘急性发作期患儿,采用随机数字表法分为观察组和对照组各45 例,对照组患儿采用止咳平喘、抗感染等常规治疗,观察组在此基础上加用布地奈德雾化吸入治疗。连续治疗14 d后评价临床疗效,比较两组患儿治疗前后肺功能变化、血清免疫球蛋白E(IgE)、C反应蛋白(CRP)、白细胞介素-6(IL-6)水平以及喘息、咳嗽、肺部哮鸣音、呼吸困难等临床症状缓解时间。结果:观察组治疗总有效率为91.11%,显著高于对照组的80.00%,差异有统计学意义(P<0.05);两组患儿治疗后FVC、FEV1水平、FEV1/FVC 值均显著升高,且观察组治疗后显著低于对照组,差异有统计学意义(P<0.05);两组治疗后血清IgE、CRP、IL-6 水平均显著降低,且观察组治疗后显著低于对照组,差异有统计学意义(P<0.05);观察组喘息、咳嗽、肺哮鸣音、呼吸困难缓解时间显著短于对照组,差异有统计学意义(P<0.05)。结论:常规止咳平喘、抗感染治疗基础上加用布地奈德雾化吸入治疗能显著提升小儿哮喘急性发作期临床疗效,改善肺功能,降低气道炎性反应,加速呼吸道症状缓解。

Budesonide Aerosol Inhalation in the Treatment of Children with Acute Attack of Asthma and Changes of Serum Inflammatory Factors

Objective: To investigate the efficacy of budesonide aerosol inhalation in the treatment of children with acute attack of asthma and changes of serum inflammatory factors. Methods: Totally 90 children with acute attack of asthma admitted into our hospital from Jan. 2016 to Dec. 2017 were extracted to be divided into the observation group and the control group via the random number table, with 45 cases in each group. The control group were treated with routine cough, asthma and anti-infection treatment, and the observation group received budesonide aerosol inhalation based on the control group. Comprehensive clinical efficacy was evaluated after 14 d of continuous treatment. Changes in pulmonary function, levels of serum immunoglobulin E (IgE), C-reactive protein (CRP),interleukin-6 (IL-6), and relief time of clinical symptoms such as wheezing, cough, lung rales and dyspnea in two groups were compared. Results: The total effective rate of the observation group was 91.11%, significantly higher than that of the control group (80.00%), and the difference was statistically significant (P<0.05). After treatment, the FVC, FEV1 and FEV1/FVC of two groups increased significantly, and the observation group was significantly higher than the control group, with statistically significant differences (P<0.05). The levels of serum IgE, CRP and IL-6 of two groups decreased significantly, and the observation group was significantly lower than the control group, with statistically significant differences (P<0.05). The relief time of wheezing, cough, lung rales and dyspnea in observation group was shorter than that of the control group (P<0.05). Conclusion: On the basis of routine cough, asthma and anti-infection treatment, budesonide aerosol inhalation can significantly improve the clinical efficacy of children with acute attack of asthma, improve the lung function, reduce the airway inflammatory response, and accelerate the regression of respiratory symptoms.